Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.35 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.34 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17039548 | 0.83 | KCNK3 (0.44) | MPLKDM4EGAAKCNK3KCNK9 | |
| SCHEMBL13019837 | 0.81 | SLC6A2 (0.43) | KCNH2L3MBTL1TRPA1 | |
| SCHEMBL17037514 | 0.80 | MPL (0.42) | MPLPDE2AKDM4EKCNK3KCNK9 | |
| SCHEMBL6764211 | 0.80 | IDO1 (0.37) | MPLKCNH2HSD11B1 | |
| SCHEMBL900977 | 0.79 | MPL (0.44) | MPLKDM4EKCNK3KCNK9ALDH1A1 | |
| SCHEMBL18308923 | 0.79 | KCNH2 (0.38) | MPLKCNH2GAAALDH1A1TRPA1 | |
| SCHEMBL19240448 | 0.79 | KCNK3 (0.49) | MPLKCNK3KCNK9ALDH1A1 | |
| SCHEMBL28675923 | 0.79 | ALDH1A1 (0.46) | MPLALDH1A1L3MBTL1 | |
| SCHEMBL1401600 | 0.78 | MPL (0.46) | MPLKCNH2PDE2AKDM4EGRIA1 | |
| SCHEMBL1566030 | 0.78 | KCNH2 (0.37) | MPLKCNH2GAAHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230071620-A1 | PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-03-09 | — | — | US | disclosed |
| US-20180022766-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-20180022766-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-9732104-B2 | Ether compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160362433-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20150239920-A1 | Ether Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362433-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, C9, TFPI | MPL 121/4885KCNH2 3016/4885PDE2A 4490/4885 |
| US-20230071620-A1 | PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | MPL 521/4885KCNH2 2608/4885PDE2A 1004/4885 |
| US-20180022766-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | TFPI, CFD, C9 | MPL 1390/4885KCNH2 2742/4885PDE2A 4711/4885 |
| US-20150239920-A1 | Ether Compounds for Treatment of Complement Mediated Disorders | TFPI, CFD, C9 | MPL 1390/4885KCNH2 2742/4885PDE2A 4711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.